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Abstract 
Background: Current treatments for hypercalcemia caused by lung cell carcinomas 
producing parathyroid hormone-related peptide (PTH-rp) have limited efficacy, probably 
because of their lack of effect on PTH-rp secretion. In this case study we explored the 
efficacy of the calcimimetic cinacalcet as suppressor of PTH-rp production.  
Patient: A 57-year-old male with severe and recurrent hypercalcemia induced by a PTH-rp-
producing squamous cell lung carcinoma, stage cT4N3M1b, poorly responding to standard 
treatments.  
Results: Serum PTH-rp levels were not affected by saline, calcitonin or zoledronate. PTH-rp 
decreased during chemotherapy and cinacalcet monotherapy. The combination of 
chemotherapy plus cinacalcet was most effective in rapidly reducing serum calcium and PTH-
rp.  
Conclusion: This case study is the first to suggest that cinacalcet may be of value in some 
cases of PTH-rp-dependent hypercalcemia. Corroborative evidence is needed. 
 
Introduction 
Humoral hypercalcemia of malignancy (HHM) is the most common paraneoplastic 
syndrome in cancer patients. In 80% of cases HHM is caused by the production of 
parathyroid hormone-related peptide (PTH-rp) [1, 2]. It is most common in squamous 
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cell carcinoma of the lung, with a reported incidence of 5–10%, depending on the stage 
of disease [3, 4]. 
PTH and PTH-rp both target the PTH receptors in bone and kidney in a similar way. 
They simultaneously stimulate osteoclastic bone resorption, increase renal calcium 
reabsorption and promote the formation of 1,25-dihydroxyvitamin D [5]. Due to this 
combination of actions on calcium absorption, mobilization and excretion, PTH-rp-
producing carcinomas can cause a rapid and excessive rise in serum calcium that is 
often resistant to conventional treatment with forced hydration and intravenous 
bisphosphonates, because these interventions do not block all effects of PTH-rp. 
Moreover, the effects of bisphosphonates on bone resorption are usually short-lived, 
because PTH-rp levels are not affected and the stimulus for enhanced bone resorption 
is maintained. The efficacy of bisphosphonates is inversely related to serum PTH-rp [6]. 
In view of these findings it is conceivable that suppression of PTH-rp secretion or 
blockade of PTH-rp activity could be beneficial. We hypothesized that it might help to 
reduce serum calcium, as well as to reduce tumor progression. The latter is suggested 
by observations that PTH-rp promotes spreading of bone metastasis and can act as an 
autocrine growth factor inhibiting lung cancer cell apoptosis [7]. 
Present day knowledge of factors affecting cancer cell PTH-rp production is mainly 
limited to in vitro observations in carcinoma cell lines. These studies have shown that 
calcitonin, epidermal growth factor, transforming growth factor beta, insulin and 
cycloheximide increase PTH-rp transcription [8–11], that cAMP promotes the release of 
PTH-rp [12], and that 1,25-OH vitamin D agonists and IL-4 can suppress PTH-rp gene 
expression [8, 10, 11]. There is also evidence that the calcium-sensing receptor (CaR) is 
important for the regulation of PTH-rp secretion in normal as well as in malignant cells 
[13]. Normal cell lines producing PTH-rp respond to CaR activation with a decrease in 
PTH-rp secretion, whereas some cancer cell lines may respond with an increase in PTH-
rp release [13–15]. This reversal in response has been shown in some breast, prostate, 
and testicular cancer cell lines, a phenomenon that has been attributed to a switch in 
the type of G-protein that is activated by the CaR [14–16]. Reversal in response is not a 
universal characteristic of cancer cells. A human small cell lung carcinoma cell line 
expressing the CaR and producing PTH-rp, responded like normal cells, i.e. increasing 
the Ca2+ concentration in the growth medium reduced PTH-rp secretion, whereas a 
decrease in Ca2+ was associated with an increase in PTH-rp release [15]. The type of 
response to CaR activation of squamous cell lung carcinomas is currently not known. 
When a patient presented with severe and treatment-resistant hypercalcemia 
caused by a PTH-rp producing lung carcinoma, we considered that the calcimimetic 
cinacalcet might be a reasonable candidate compound to achieve PTH-rp suppression. 
We hypothesized that if this tumor expressed CaRs, PTH-rp production might be 
suppressible with cinacalcet, and that this could have a beneficial effect on serum 
calcium and possibly on survival as well. Animal studies support that line of thought. 
Animals treated with humanized anti-PTH-rp antibodies showed a resolution of 
hypercalcemia, inhibition of bone metastases and disappearance of cachexia [5, 17]. 
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Materials and Methods 
Serum intact PTH (normal range: 1.3–6.8 pmol/l) was measured by a solid-phase, two-site 
chemiluminescent enzyme-labeled immunometric assay (Immulite 2500, Siemens, Los Angeles, Calif., 
USA), with an intra- and interassay precision of <6 and <9%, respectively. PTH-rp (normal range: <0.6 
pmol/l) was measured by an immunoradiometric assay (Immunotech, Prague, Czech Republic), with 
an intra- and interassay precision of <8.9 and <10%, respectively. All other laboratory parameters 
were measured by routine clinical chemistry assays (Roche Diagnostics, Almere, The Netherlands). 
The serum calcium (Ca) levels referred to in the text and in the figures represent total calcium levels 
corrected for albumin according to the equation: Ca in mmol/l = total calcium – (0.025 × albumin in 
g/l) + 1. Serum ionized calcium (Ca2+) was measured with a blood gas analyzer (OMNI Roche, 
Mannheim, Germany). 
Case 
A 57-year-old man presented with recent onset weakness, severe constipation and 5 kg weight 
loss. Physical examination was unremarkable but laboratory investigation revealed renal failure, 
severe hypercalcemia, and an elevated PTH-rp: serum creatinine 214 μmol/l, Ca 4.56 mmol/l, 
phosphate 0.91 mmol/l, PTH <1 pmol/l, and PTH-rp 5.8 pmol/l. Additional investigations led to a 
diagnosis of squamous cell carcinoma of the lung, stage cT4N3M1b, with metastases in bone and liver. 
Intravenous fluid replacement (NaCl 0.9%, 4 l/24 h), combined with calcitonin 450 IU subcutaneously 
twice a day for 5 days, and pamidronate 90 mg intravenously in week 1 and 2 reduced serum Ca to 
2.84 mmol/l (data not shown). A fortnight later serum Ca had increased again to 4.40 mmol/l. Fluid 
replacement was started again (fig. 1, blue bar), now in combination with calcitonin 250 IU twice a 
day subcutaneously for 5 days (salmon bar) and a single dose of zoledronate 5 mg intravenously 
(purple dot). These 5 days of combination treatment reduced serum Ca to 3.20 mmol/l, but there was 
no effect on serum PTH-rp levels. On the 6th day serum Ca rose again to 3.50 mmol/l, and after 
obtaining informed consent, cinacalcet was started, 30 mg twice a day, and continued for a period of 
15 days (green bar). Chemotherapy, consisting of cycles of carboplatin and gemcitabine, was started 
two days later (black asterisks). During combined chemotherapy and cinacalcet treatment, serum 
PTH-rp decreased rapidly, and this was finally associated with a fall in serum Ca into the 
hypocalcemic range (ionized calcium 0.86 mmol/l). Cinacalcet was discontinued, and the next day a 
prompt rise in serum PTH was observed, from an undetectable level to a concentration of 5.1 pmol/l, 
associated with a normalization of serum Ca. Subsequently, the patient received three cycles of 
chemotherapy. Each cycle was preceded by a gradual rise in serum PTH-rp and serum Ca, and 
followed by a decrease in both parameters. Only the first cycle of chemotherapy had been given in 
combination with cinacalcet. During this first cycle serum PTH-rp decreased from 13.2 to 0.9 pmol/l 
in 15 days. During the 2nd, 3rd, and 4th chemotherapy cycles the decreases in PTH-rp were much 
smaller and slower than during the 1st cycle. Just before the 4th cycle serum Ca had increased to 3.71 
mmol/l and forced hydration and chemotherapy was required to normalize the serum Ca level again. 
Chemotherapy resulted in stable disease according to RECIST-criteria, but soon after the 4th cycle 
serum Ca rose again to about 3.50 mmol/l. Hydration and cinacalcet was started in a dose of 60 mg 
twice daily. Although PTH-rp decreased from 8.7 to 5.0 pmol/l, this alone did not immediately affect 
serum Ca levels. Calcium levels stabilized around 3.50–3.80 mmol/l. Only when a 5-mg dose of 
zoledronate was given in addition, serum Ca decreased to a value below 3.00 mmol/l, and the patient 
could be discharged on cinacalcet 60 mg twice a day. Unfortunately, the Ca-lowering effect was short-
lived, and 9 days later hospitalization was necessary again and another dose of zoledronate was given. 
When the patient was informed that the chest X-ray showed progression of the tumor, he declined 
further treatment and was discharged on request. Two weeks later he died at home. 
To examine the importance of PTH-rp as determinant of serum Ca levels in this patient, ionized 
serum calcium was plotted as a function of serum PTH-rp (fig. 2). Despite the many different 
interventions to reduce serum Ca2+, there was a strong correlation between the two variables. PTH-rp 
levels explained 71% of the variance in serum Ca2+. 
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Discussion 
To our knowledge, this is the first case where cinacalcet was used to treat PTH-rp-
related hypercalcemia. It is not easy to assess without doubt which factors contributed 
significantly to the changes in serum PTH-rp and Ca because the analysis is hampered 
by the simultaneous use of different types of treatments during various periods,. 
Although recognizing that the evidence is not conclusive, we believe that several 
observations support the conclusion that cinacalcet by itself did have PTH-rp-
suppressive effects, and that further evaluation of this use of cinacalcet in a larger 
setting is warranted. 
During the first five days, when a combination of saline, calcitonin and zoledronate 
was given, serum PTH-rp did not change, and it was concluded that none of these 
agents had an effect on PTH-rp secretion. During the next two weeks the patient was 
treated with cinacalcet 30 twice daily in combination with chemotherapy. In this period 
a major decline in serum PTH-rp occurred. Thus, one or both factors must have reduced 
PTH-rp secretion. Tumor load reduction by chemotherapy is likely to have contributed 
to the decrease in PTH-rp levels, and this is supported by the declines in PTH-rp that 
occurred during each of the next cycles of chemotherapy not combined with other 
treatment. Two observations are likely to suggest that cinacalcet has also exerted PTH-
rp lowering effects. First, the decline in PTH-rp during the first cycle of chemotherapy 
was much steeper than during the next three cycles when no cinacalcet was given. 
Second, when hypercalcemia recurred after the fourth cycle of chemotherapy, 
cinacalcet monotherapy induced a consistent decline in serum PTH-rp and prevented a 
further rise in serum Ca. The observation that serum Ca did not normalize during this 
period does not dispute the effect of cinacalcet on PTH-rp secretion. It merely indicates 
that osteoclast activation still continued at a certain level because PTH-rp suppression 
was not complete. Additional bisphosphonate treatment was needed to further reduce 
the Ca efflux from bone. 
Figure 2 illustrates the importance of PTH-rp reduction in HHM and shows that 71% 
percent of the variance in serum ionized Ca (Ca2+) was explained by serum PTH-rp 
levels. The relationship was very strong for serum Ca2+ levels up to 1.75 mmol/l and 
then weakened substantially. The latter is attributed to the confounding effects of the 
various treatments that were started when serum Ca2+ was in this high range. These 
treatments disturbed the relationship between PTH-rp and serum Ca2+ considerably 
because they affected serum Ca2+ without altering serum PTH-rp. 
The present case also illustrates that the use of cinacalcet in PTH-rp-dependent 
hypercalcemia may not be without risk and should be closely monitored. During the 
first treatment period serum Ca dropped into the hypocalcemic range. This did not 
occur when chemotherapy was given alone, and thus this effect must be related to the 
use of cinacalcet. The hypocalcemic episode is attributed to cinacalcet’s suppression of 
the parathyroid glands. As shown in figure 1, PTH increased rapidly when cinacalcet 
was discontinued, and this restored serum calcium within a few days. 
It is also important to note that the response to cinacalcet may vary from case to 
case. It is likely to depend on the degree of CaR expression and the presence of a 
normal post-receptor signaling pathway. The response to cinacalcet may also vary 
among the various types of malignancies, and maybe even among patients with similar 
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types of cancer. In vitro studies have shown that breast and prostate cancer cell lines 
may respond to CaR agonists by increasing PTH-rp secretion, thus creating a vicious 
cycle [13]. It is currently not known whether this reversal in CaR responsiveness, an 
observation made in cell cultures only, can also occur in vivo. In the present case, PTH-
rp levels decreased on both occasions where cinacalcet was used, indicating that CaR 
responsiveness was not reversed. 
At present, it is not known for how long cinacalcet may exert PTH-rp-suppressive 
effects in cancer cells. In the final weeks of his life the patient’s serum PTH-rp levels 
increased rapidly, despite the prescription of cinacalcet. As we didn’t measure 
cinacalcet serum levels we do not know whether there was reduced patient 
compliance, loss of cinacalcet’s suppressive action or rapid tumor progression. 
It is concluded that reduction of PTH-rp is an important target to reduce serum Ca in 
HHM. It can be achieved by tumor mass reduction by surgery, chemotherapy or 
radiotherapy. Although the evidence is not conclusive, the present case at least suggests 
that PTH-rp production can be reduced by the use of cinacalcet. It is well recognized 
that confirmation is needed and that many aspects require further evaluation. For 
example, it is currently not known how often PTH-rp-producing lung carcinomas 
express the CaR, what percentage responds to cinacalcet with a decrease in PTH-rp, 
whether cinacalcet-mediated PTH-rp suppression affects survival in lung cancer 
patients, and whether cinacalcet may be effective in other types of PTH-rp-producing 
cancers. 
Disclosure Statement 
None of the authors have any conflict of interest to report. This research did not receive any 
specific grant from any funding agency in the public, commercial or not-for-profit sector. 
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Fig. 1. Calcium and PTH-rp responses to various treatments. Black bar: in-hospital stay, blue bar: 
NaCl 0.9% intravenously, salmon bar: calcitonin subcutaneously twice a day, purple dot: single dose 
of zoledronate 5 mg intravenously, black asterisk: chemotherapy, green bar: cinacalcet treatment.  
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Fig. 2. PTH-rp as determinant of serum ionized calcium concentration. 
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